Skip to main content
NTLA
NASDAQ Life Sciences

Intellia 将于 4 月 27 日公布 Lonvoguran Ziclumeran 的关键性第三阶段 HAELO 数据

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$15.08
Mkt Cap
$1.61B
52W Low
$6.83
52W High
$28.25
Market data snapshot near publication time

summarizeSummary

Intellia Therapeutics 宣布，将于 2026 年 4 月 27 日公布其全球第三阶段 HAELO 临床试验的顶级数据，该试验是关于 lonvoguran ziclumeran 在遗传性血管神经性水肿（HAE）方面的。这一公告为公司设定了一个关键的近期催化剂，因为第三阶段的结果对于监管批准和商业化至关重要。考虑到 Intellia 的 16 亿美元市值，该试验的结果具有高度的重要性，可能会显著影响股票价格。交易者将密切关注这些结果，这些结果将在同一天的网络广播中进行讨论。

在该公告发布时，NTLA的交易价格为$15.08，交易所为NASDAQ，所属行业为Life Sciences，市值约为$16.1亿。 52周交易区间为$6.83至$28.25。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed NTLA - Latest Insights

NTLA
Apr 27, 2026, 9:13 AM EDT
Filing Type: 8-K
Importance Score:
9
Intellia Reports Landmark Phase 3 Results for Gene-Editing Therapy Lonvo-z, Initiates BLA Submission
Sentiment: Positive
View Wiseek Article
NTLA
Apr 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Intellia's Gene-Editing Therapy Achieves 87% Attack Reduction in Phase 3 HAE Trial, BLA Submission Initiated
Sentiment: Positive
View Wiseek Article
NTLA
Apr 24, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Intellia to Report Pivotal Phase 3 HAELO Data for Lonvoguran Ziclumeran on April 27
Sentiment: Neutral
View Wiseek Article
NTLA
Mar 02, 2026, 4:13 PM EST
Filing Type: 424B5
Importance Score:
7
Intellia Therapeutics Finalizes Terms for $400M At-The-Market Offering
Sentiment: Neutral
View Wiseek Article
NTLA
Mar 02, 2026, 8:23 AM EST
Source: Unknown
Importance Score:
9
Intellia Therapeutics Expands ATM Program to $1.04 Billion, Signaling Massive Potential Dilution
Sentiment: Negative
View Wiseek Article
NTLA
Mar 02, 2026, 8:16 AM EST
Filing Type: 8-K
Importance Score:
8
FDA Lifts Clinical Hold on Key Phase 3 Trial; Expands ATM Program to $400M
Sentiment: Neutral
View Wiseek Article
NTLA
Mar 02, 2026, 7:36 AM EST
Source: Reuters
Importance Score:
9
FDA Lifts Clinical Hold on Intellia's Magnitude Phase 3 ATTR-CM Trial
Sentiment: Positive
View Wiseek Article
NTLA
Feb 26, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
7
Intellia Therapeutics Files Comprehensive 2025 Annual Report, Details Clinical Progress, Financials, and Liquidity
Sentiment: Neutral
View Wiseek Article
NTLA
Feb 26, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
8
Intellia Reports Strong Q4/FY2025 Results, Advances Lonvo-z Towards Mid-2026 Phase 3 Data & 2027 Launch
Sentiment: Positive
View Wiseek Article
NTLA
Jan 27, 2026, 8:19 AM EST
Filing Type: 8-K
Importance Score:
8
FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for ATTRv-PN
Sentiment: Positive
View Wiseek Article